购物车
您的购物车当前为空
KRAS G12D inhibitor 29 (Compound Formula (I)) 是一种口服活性和选择性的KRASG12D抑制剂,通过阻断KRASG12D介导的下游信号抑制肿瘤细胞增殖。KRAS G12D inhibitor 29 适用于研究与KRASG12D突变相关的癌症,包括胰腺癌、肺癌、结肠癌。
KRAS G12D inhibitor 29 (Compound Formula (I)) 是一种口服活性和选择性的KRASG12D抑制剂,通过阻断KRASG12D介导的下游信号抑制肿瘤细胞增殖。KRAS G12D inhibitor 29 适用于研究与KRASG12D突变相关的癌症,包括胰腺癌、肺癌、结肠癌。

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | 待询 | 10-14周 | |
| 50 mg | 待询 | 10-14周 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
凭借在化合物合成方面的丰富经验,我们可以根据您的研究需求为该产品提供快速定制合成服务。
| 产品描述 | KRAS G12D inhibitor 29 (Compound Formula (I)) is an orally active and selective inhibitor of KRASG12D. It effectively blocks KRASG12D-mediated downstream signaling pathways, thereby inhibiting the proliferation of tumor cells. This compound holds potential for research into cancers associated with KRASG12D mutations, such as pancreatic cancer, lung cancer, and colorectal cancer. |
| 分子量 | 649.63 |
| 分子式 | C31H33F6N7O2 |
| CAS No. | 3018057-89-8 |
| Smiles | FC=1C2=C3C(N4[C@]([C@H](C)OC3=NC1C5=C(C(F)(F)F)C(C)=C(F)C(N)=C5)([C@]6(N[C@@](C4)(CC6)[H])[H])[H])=NC(OC[C@@]78N(C[C@H](F)C7)CCC8)=N2 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 |
对于不同动物的给药剂量换算,您也可以参考 更多